The global gluten-free products market is on track to reach $19.2 billion by 2031—more than doubling its current size. According to a market analysis published by GlobeNewswire, gluten-free is one of the fastest-growing segments in packaged food. That raises a question worth asking carefully: does a bigger market make life safer for people with celiac disease, or just busier?
The answer is complicated—and I think the complexity matters to celiac families.
What This Means for You
At first glance, a $19.2 billion gluten-free market sounds like a win. More money flowing into the sector means more products on shelves, more competition, and more pressure to improve quality. For families navigating celiac disease, that can translate to better variety and, over time, lower prices as manufacturers achieve scale.
But market growth and celiac-safe growth are not the same thing. The gluten-free market runs primarily on lifestyle consumers—people who choose gluten-free for general wellness, digestive comfort, or perceived health benefits rather than because they have celiac disease or a diagnosed medical need. Estimates consistently put this group at roughly 60 to 70 percent of all gluten-free purchasing. Food companies chasing a $19 billion market are largely chasing those buyers.
That distinction matters for celiac families. Products aimed at lifestyle consumers don’t always meet the safety threshold celiac patients require. A snack labeled “gluten-free” might be manufactured in a facility that also handles wheat, creating cross-contact risk that a lifestyle buyer won’t notice and a celiac patient cannot ignore. The label alone is not a safety guarantee.
The more encouraging side: a growing market also funds the kind of innovation that does benefit celiac patients. Dedicated gluten-free manufacturing facilities become more economically viable at scale. Third-party certification programs have more producers to recruit and more market pressure to use. And even lifestyle-driven product development often produces safer formulations as manufacturers learn how to control gluten in their supply chains. Celiac families benefit from that learning whether or not they were the intended audience.
The practical takeaway for right now: more products means more options, but it does not reduce the work of verifying which products are safe. That job stays the same.
Key Takeaways
- The gluten-free products market is projected to reach $19.2 billion by 2031, roughly double its current size.
- Most market growth is driven by lifestyle and wellness consumers, not celiac patients.
- A larger market means more products and greater investment in gluten-free manufacturing—both of which can benefit celiac families indirectly.
- “Gluten-free” on a label does not guarantee celiac-safe manufacturing; third-party certification remains the most reliable signal.
- Celiac advocates have more leverage as the market grows—but enforcement of safety standards still depends on pressure from the celiac community specifically.
The Science
Want to understand the economics and food science behind these projections—and what they actually predict for celiac safety? We’ll walk you through the technical details below and define every term. No medical degree required.
How Market Projections Work
Research firms calculate a market’s projected value using a metric called CAGR (compound annual growth rate)—the annualized percentage by which a market is expected to expand year over year. Going from roughly $8 to $9 billion today to $19.2 billion by 2031 implies a CAGR of approximately 10 to 12 percent annually. That’s unusually high for a packaged food category; the broader food market typically grows at 3 to 5 percent per year.
The high CAGR reflects two forces compounding together: rising celiac disease diagnoses and broader awareness of non-celiac gluten sensitivity (NCGS)—a condition in which people experience gluten-related symptoms without the autoimmune intestinal damage that defines celiac disease—alongside continued growth in lifestyle-motivated gluten-free purchasing.
It’s also worth noting that different research firms produce markedly different projections. We previously covered a separate analysis projecting the gluten-free food market to reach $11.5 billion by 2033—a number that looks substantially different from today’s $19.2 billion estimate. These gaps come from differences in scope: which product categories count, which geographies are included, and how firms define the “gluten-free” segment. Neither projection is wrong; both are directional signals, not precise forecasts.
The 20 ppm Standard—and Why It’s Not Enough on Its Own
The FDA defines “gluten-free” in the United States as containing fewer than 20 parts per million (ppm) of gluten. The European Union uses the same threshold. This number comes from clinical research showing that most celiac patients can consume products below 20 ppm without measurable intestinal damage.
“Most” is the operative word. Some patients react at lower concentrations. Research on individual sensitivity thresholds is still developing, and the regulatory standard reflects a population-level finding rather than a guarantee for every individual.
The Gluten Intolerance Group’s GFFS (Gluten-Free Food Service) certification holds products to 10 ppm—half the FDA standard—and requires facility inspections rather than relying solely on label claims. This is why celiac advocacy organizations consistently recommend certified products over labeled-only products. A “gluten-free” label tells you the manufacturer’s intent; a certification tells you an auditor verified it.
A market of $19.2 billion contains both kinds of products. Knowing which is which still requires looking beyond the front of the package.
Why Lifestyle Buyers Still Matter to Celiac Patients
Here’s an economic reality that celiac families rarely discuss: the celiac disease population alone—approximately 1 percent of people globally, or roughly 3 million Americans—is not large enough to sustain a $19 billion market. The lifestyle buyer is what makes that scale possible.
When wellness consumers drive demand for gluten-free pasta, bread, and snack foods, food manufacturers invest in dedicated production lines and tighter manufacturing controls to serve that demand profitably. Those same lines and controls benefit celiac patients. The falling prices and expanding variety that celiac families enjoy at the grocery store are partly subsidized by buyers who don’t medically need gluten-free products at all.
The risk runs in the opposite direction as well. A mainstream food company treating gluten-free as a marketing opportunity may produce GF products on shared lines with minimal investment in cross-contact controls—correctly calculating that most of its customers won’t be affected. That is exactly where celiac patients get hurt.
What a Celiac Parent Actually Watches For
My son has celiac disease, which means every time a product enters the gluten-free market, the relevant question isn’t how many billions the category is worth. It’s whether this specific product was made safely.
A growing market gives celiac families more options to evaluate—it does not reduce the evaluation. What’s worth watching: third-party certification logos on packaging, transparent facility disclosures on brand websites, and whether a company is actively marketing to the celiac community (a signal of investment in safety standards) versus broadly marketing to wellness consumers (a signal to look more carefully at manufacturing claims).
The long-term trajectory here is genuinely encouraging. More capital in the sector funds better manufacturing technology, more rigorous supply chain controls, and more producers who find it economically worthwhile to pursue certification. A $19 billion market has more to lose from a high-profile cross-contact incident than a $5 billion one did—and that changes the incentives for manufacturers.
But the size of the market has never been the measure of safety for celiac patients. Safety is measured one product at a time, at the manufacturing facility level. That work doesn’t change with the market forecast.
Related Coverage
References
- GlobeNewswire. Gluten Free Products Market to Reach $19.2 Billion by 2031. Published July 16, 2026. Read the report
- U.S. Food and Drug Administration. Gluten-Free Labeling of Foods. FDA.gov.
- Gluten Intolerance Group. GFFS Certification Program. GlutenFreeFS.com.